Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovaBay Pharmaceuticals (NBY) Other Operating Expenses (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Other Operating Expenses for 13 consecutive years, with $87000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Operating Expenses rose 148.57% to $87000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $676000.0, a 178.15% increase, with the full-year FY2024 number at -$865000.0, changed N/A from a year prior.
  • Other Operating Expenses was $87000.0 for Q3 2025 at NovaBay Pharmaceuticals, down from $589000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $8.7 million in Q4 2022 to a low of -$900000.0 in Q1 2024.
  • A 4-year average of $1.8 million and a median of $1.8 million in 2021 define the central range for Other Operating Expenses.
  • Biggest YoY gain for Other Operating Expenses was 303.3% in 2022; the steepest drop was 1.13% in 2022.
  • NovaBay Pharmaceuticals' Other Operating Expenses stood at $2.2 million in 2021, then soared by 303.3% to $8.7 million in 2022, then crashed by 99.6% to $35000.0 in 2024, then skyrocketed by 148.57% to $87000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Other Operating Expenses are $87000.0 (Q3 2025), $589000.0 (Q1 2025), and $35000.0 (Q3 2024).